The MedicalXpress summary of the 52-study meta-analysis (n≈978,000 Europeans; 128,000 cases) correctly notes expansion to 91 loci with 16 novel signals, yet underplays how this GWAS reinforces a polygenic architecture centered on microglial activation rather than solely plaque clearance. As an observational design reliant on European-ancestry biobanks (EADB, ADGC, FinnGen), the work carries inherent selection bias and lacks RCT-level causal validation, though its scale dwarfs prior efforts. Enrichment analyses highlight endosomal-lysosomal trafficking and tau-related lipid metabolism genes expressed predominantly in microglia—pathways that predate the 2022 Bellenguez et al. 75-loci map (Nature Genetics) and align with emerging single-cell data from the 2023 Mathys et al. Nature study showing microglial states driving neuroinflammation independently of amyloid load. Mainstream outlets fixate on anti-amyloid antibodies while sidelining these loci's implications for early immune modulation; the derived polygenic risk score doubles odds of severe tau pathology yet explains only modest variance, echoing limitations flagged in the 2024 Jansen et al. Lancet Neurology review of PRS utility across ancestries. Conflicts of interest remain undisclosed in the press release but typically involve pharma ties in ADGC consortia. This genetic map thus redirects attention toward precision prevention via lipid-immune targets rather than late-stage plaque removal.